30
Participants
Start Date
August 5, 2020
Primary Completion Date
February 10, 2022
Study Completion Date
February 10, 2022
MAU868
MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
Placebo
250 mL D5W placebo IV to be labeled to match that of MAU868
Montefiore Medical Center, The Bronx
University of Pittsburgh Medical Center (UPMC), Pittsburgh
The Johns Hopkins University, Baltimore
Vanderbilt University Medical Center, Nashville
University of Kentucky, Lexington
University Hospitals Cleveland Medical Center, Cleveland
Washington University, St Louis
Renal Disease Research Institute, LLC, Dallas
The University of Texas Southwester Medical Center, Dallas
Houston Methodist Research Institute, Houston
Cedars-Sinai Medical Center, Los Angeles
University of Washington, Seattle
University of Alabama at Birmingham, Birmingham
Yale University, New Haven
Massachusetts General Hospital, Boston
University Health Network, Toronto
Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Est de-l'Île-de-Montréal, Montreal
The Research Institute of the McGill University Health Centre, Montreal
Vera Therapeutics, Inc.
INDUSTRY